Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer

Abstract Background Current breast cancer (BC) diagnostics include detailed pathological and genetic analysis for biological subtype identification; however, throughout the course of the disease, new alterations determining the progression of the disease or resistance to treatment appear. The tests...

Full description

Saved in:
Bibliographic Details
Main Authors: Ieva Sadzeviciene, Danielius Kaubrys, Sonata Jarmalaite
Format: Article
Language:English
Published: Cambridge University Press 2025-01-01
Series:Expert Reviews in Molecular Medicine
Subjects:
Online Access:https://www.cambridge.org/core/product/identifier/S1462399425100082/type/journal_article
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849233064443510784
author Ieva Sadzeviciene
Danielius Kaubrys
Sonata Jarmalaite
author_facet Ieva Sadzeviciene
Danielius Kaubrys
Sonata Jarmalaite
author_sort Ieva Sadzeviciene
collection DOAJ
description Abstract Background Current breast cancer (BC) diagnostics include detailed pathological and genetic analysis for biological subtype identification; however, throughout the course of the disease, new alterations determining the progression of the disease or resistance to treatment appear. The tests based on liquid biopsy allow minimally invasive real-time monitoring of tumour-specific alteration during the entire disease treatment. Tumour-specific genetic material fragments occur in bodily fluids, and cell-free nucleic acids are a convenient tool for analysing genetic and epigenetic changes in tumours. Evidence for the diagnostic and prognostic value of epigenetic biomarkers is gradually increasing. Although, up to date, there is limited access to in vitro diagnostic (IVD) epigenetic liquid biopsy-based tests for BC management, the data on the clinical potential of such tests and biomarkers are accumulating rapidly. Methods In this review, we focused on research involving cell-free DNA methylation biomarkers in blood serum or plasma samples from BC patients. Results Our review systematises data from genome-wide and targeted studies of DNA methylation changes in liquid biopsies from BC patients, aiming to highlight the most critical biomarkers suitable for early BC diagnosis, treatment personalisation and prognosis. Conclusion In summary, cell-free DNA methylation biomarkers show strong potential to enhance breast cancer diagnosis, prognosis, and personalised treatment through integrated clinical profiling.
format Article
id doaj-art-ada2759efcf44c5c857e16227876f366
institution Kabale University
issn 1462-3994
language English
publishDate 2025-01-01
publisher Cambridge University Press
record_format Article
series Expert Reviews in Molecular Medicine
spelling doaj-art-ada2759efcf44c5c857e16227876f3662025-08-20T12:57:28ZengCambridge University PressExpert Reviews in Molecular Medicine1462-39942025-01-012710.1017/erm.2025.10008Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast CancerIeva Sadzeviciene0https://orcid.org/0000-0003-1953-040XDanielius Kaubrys1Sonata Jarmalaite2Institute of Biosciences, Life Sciences Center, https://ror.org/03nadee84 Vilnius University , Vilnius, LithuaniaInstitute of Biosciences, Life Sciences Center, https://ror.org/03nadee84 Vilnius University , Vilnius, LithuaniaInstitute of Biosciences, Life Sciences Center, https://ror.org/03nadee84 Vilnius University , Vilnius, Lithuania https://ror.org/04w2jh416 National Cancer Institute , Biobank, Vilnius, LithuaniaAbstract Background Current breast cancer (BC) diagnostics include detailed pathological and genetic analysis for biological subtype identification; however, throughout the course of the disease, new alterations determining the progression of the disease or resistance to treatment appear. The tests based on liquid biopsy allow minimally invasive real-time monitoring of tumour-specific alteration during the entire disease treatment. Tumour-specific genetic material fragments occur in bodily fluids, and cell-free nucleic acids are a convenient tool for analysing genetic and epigenetic changes in tumours. Evidence for the diagnostic and prognostic value of epigenetic biomarkers is gradually increasing. Although, up to date, there is limited access to in vitro diagnostic (IVD) epigenetic liquid biopsy-based tests for BC management, the data on the clinical potential of such tests and biomarkers are accumulating rapidly. Methods In this review, we focused on research involving cell-free DNA methylation biomarkers in blood serum or plasma samples from BC patients. Results Our review systematises data from genome-wide and targeted studies of DNA methylation changes in liquid biopsies from BC patients, aiming to highlight the most critical biomarkers suitable for early BC diagnosis, treatment personalisation and prognosis. Conclusion In summary, cell-free DNA methylation biomarkers show strong potential to enhance breast cancer diagnosis, prognosis, and personalised treatment through integrated clinical profiling. https://www.cambridge.org/core/product/identifier/S1462399425100082/type/journal_articlebreast cancercell-free DNA (cfDNA)DNA hypermethylationDNA methylation biomarkersgenome-wide methylationliquid biopsy
spellingShingle Ieva Sadzeviciene
Danielius Kaubrys
Sonata Jarmalaite
Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer
Expert Reviews in Molecular Medicine
breast cancer
cell-free DNA (cfDNA)
DNA hypermethylation
DNA methylation biomarkers
genome-wide methylation
liquid biopsy
title Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer
title_full Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer
title_fullStr Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer
title_full_unstemmed Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer
title_short Liquid Biopsy-Based DNA Methylation Biomarkers for Precision Medicine in Breast Cancer
title_sort liquid biopsy based dna methylation biomarkers for precision medicine in breast cancer
topic breast cancer
cell-free DNA (cfDNA)
DNA hypermethylation
DNA methylation biomarkers
genome-wide methylation
liquid biopsy
url https://www.cambridge.org/core/product/identifier/S1462399425100082/type/journal_article
work_keys_str_mv AT ievasadzeviciene liquidbiopsybaseddnamethylationbiomarkersforprecisionmedicineinbreastcancer
AT danieliuskaubrys liquidbiopsybaseddnamethylationbiomarkersforprecisionmedicineinbreastcancer
AT sonatajarmalaite liquidbiopsybaseddnamethylationbiomarkersforprecisionmedicineinbreastcancer